Coldstream Capital Management Inc. Buys 81 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Coldstream Capital Management Inc. increased its position in United Therapeutics Co. (NASDAQ:UTHR) by 4.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,087 shares of the biotechnology company’s stock after buying an additional 81 shares during the period. Coldstream Capital Management Inc.’s holdings in United Therapeutics were worth $665,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Andra AP fonden grew its stake in United Therapeutics by 5.7% in the second quarter. Andra AP fonden now owns 35,100 shares of the biotechnology company’s stock valued at $11,181,000 after acquiring an additional 1,900 shares during the period. Texas Permanent School Fund Corp lifted its holdings in shares of United Therapeutics by 19.0% in the 2nd quarter. Texas Permanent School Fund Corp now owns 48,928 shares of the biotechnology company’s stock worth $15,586,000 after purchasing an additional 7,799 shares in the last quarter. Choreo LLC acquired a new stake in United Therapeutics in the 2nd quarter valued at $336,000. Prudential PLC grew its position in United Therapeutics by 10.0% in the 2nd quarter. Prudential PLC now owns 9,314 shares of the biotechnology company’s stock valued at $2,967,000 after purchasing an additional 847 shares during the period. Finally, LSV Asset Management increased its stake in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $313.91, for a total transaction of $1,130,076.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $40,808.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $313.91, for a total transaction of $1,130,076.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $40,808.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at $947,597.55. The disclosure for this sale can be found here. Insiders have sold a total of 114,522 shares of company stock worth $37,671,474 over the last ninety days. 12.50% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $341.11 on Friday. The company has a market capitalization of $15.13 billion, a PE ratio of 16.13, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $366.08. The company has a 50-day simple moving average of $336.24 and a 200 day simple moving average of $286.30.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter in the previous year, the business earned $5.24 EPS. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, research analysts predict that United Therapeutics Co. will post 24.86 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of analyst reports. Bank of America reduced their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. UBS Group lifted their target price on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. JPMorgan Chase & Co. increased their price target on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 price objective on shares of United Therapeutics in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $350.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.